Precision Biosciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023. About Precision BioSciences, Inc. Precision BioSciences, Inc.

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company's Senior Leadership Team (SLT).

Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference

Cellectis SA

Caribou Biosciences

Sangamo Therapeutics

Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing right now, there is likely much more to come.

There's a Lot of Upside For Emerging Gene-Editing Companies

DURHAM, N.C.--( BUSINESS WIRE )--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

DURHAM, N.C.--( BUSINESS WIRE )--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) provided supportive Type C feedback on the Company's CMC processes and analytical methods for azercabtagene zapreleucel (azer-cel; PBCAR0191). Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company's Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

DURHAM, N.C.--( BUSINESS WIRE )--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today presented a novel, product-attributes analysis of its lead CD19 allogeneic CAR T candidate, Azercabtagene Zapreleucel (azer-cel; PBCAR0191) that shows a relationship between CAR T cell composition and effective cell dose with pharmacokinetics, pharmacodynamics, and clinical outcomes. Data from this analysis, Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associated with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma, were presented today during a poster session at the American Society of Hematology Annual Meeting.

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahead of the ASH presentations. I intend to provide a brief background on Precision BioSciences and will discuss why I believe DTIL deserves a spot in the Bio Boom Portfolio.

Precision BioSciences: A Watch List Stock Going Into ASH Presentation

PHILADELPHIA--( BUSINESS WIRE )-- iECURE , a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today the completion of a $65 million Series A-1 financing. The Series A-1 financing was co-led by Novo Holdings A/S and LYFE Capital with significant participation from existing investors Versant Ventures and OrbiMed Advisors.

iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases

DURHAM, N.C.--( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company's Board of Directors and will continue as a member of the company's SAB, lending his deep expertise in antiviral drug discovery and development.

Precision BioSciences Announces Change to its Board of Directors

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting

Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022

Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre. Oral Presentation: Title: Targeting the hepat

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022. Details for the company presentation are as follows: Date: Friday, September 30, 2022 Time: 2:00 PM ET Location: Lotte New York Palace Hotel The presentation will b

Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. Details for the in-person fireside chat are as follows: Date: Tuesday, September 13, 2022 Time: 4:30 PM ET Location: Lotte New York Palace Hotel The fir

Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the company's senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO). Cindy Atwell, formerly Senior Vice President of Business Development and Alliance Management has been promoted to

Precision BioSciences Announces Senior Leadership Organizational Changes

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkin's Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2022.

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the second quarter ended June 30, 2022 and provided a business update. “This past quarter, we have executed on many important aspects of our business. From manufacturing optimization to clinical trial progress to business development and operational advancements,

Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary

Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

Precision BioSciences (DTIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Precision BioSciences (DTIL) Rating Upgrade to Strong Buy

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses payable by the

Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

News for Precision Biosciences Stock (DTIL)